Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with <i>EGFR</i> Gene Mutation–Case Report and a Literature Review
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the leading cause of cancer-related mortality worldwide. It is responsible for 80–85% of lung cancer cases. NSCLC can be divided into several groups, led by adenocarcinoma (ADC)–40–50% and squamous cell carcinoma (SCC)–20–...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/5/285 |
| _version_ | 1797500510743298048 |
|---|---|
| author | Anna Rekowska Piotr Rola Magdalena Wójcik-Superczyńska Izabela Chmielewska Paweł Krawczyk Janusz Milanowski |
| author_facet | Anna Rekowska Piotr Rola Magdalena Wójcik-Superczyńska Izabela Chmielewska Paweł Krawczyk Janusz Milanowski |
| author_sort | Anna Rekowska |
| collection | DOAJ |
| description | Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the leading cause of cancer-related mortality worldwide. It is responsible for 80–85% of lung cancer cases. NSCLC can be divided into several groups, led by adenocarcinoma (ADC)–40–50% and squamous cell carcinoma (SCC)–20–30%. The development of new molecular therapies targeting particular abnormalities such as mutations in the <i>EGFR</i> (<i>Epidermal Growth Factor Receptor</i>) gene or <i>ROS1</i> or <i>ALK</i> genes rearrangements resolved in novel strategies in advanced NSCLC management. <i>EGFR</i> mutation occurs mostly in patients with ADC and those patients are mostly females with no or light smoking history. The hereby presented patient fitted the ADC characteristics, while they were diagnosed with SCC. The unusual diagnosis implied further genetic testing, which established the occurrence of L858R substitution in exon 21 in the <i>EGFR</i> gene. A 63-year-old female was admitted to the unit due to a dry cough, pain in the right chest area and dyspnoea. When diagnosed, the patient had a peripheral mass in the right lung superior lobe (55 × 40 mm), satellite nodules in the apex of the same lung and packets of disintegrating lymph nodes. Positron Emission Tomography (PET-CT) confirmed a diffuse neoplastic process qualified as stage IV on the TNM scale. Due to <i>EGFR</i> gene mutation, the woman was administered osimertinib, however, the treatment did not succeed, and other therapeutic solutions were undertaken. The patient died 10 months after diagnosis. Patients with advanced ADC harboring <i>EGFR</i> mutation can receive osimertinib, a third-generation tyrosine kinase inhibitor (TKI), however, the use of TKIs in SCC remains controversial. In some published cases, osimertinib treatment led to success, in others, the therapy did not result in the expected final effect. Small sample groups and diverse molecular backgrounds indicate the need for further research in this field. Thus, the treatment decision-making process in those patients overall remains extremely demanding and ambiguous. |
| first_indexed | 2024-03-10T03:03:53Z |
| format | Article |
| id | doaj.art-716670b1dda54ec985ef417bddb869c5 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T03:03:53Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-716670b1dda54ec985ef417bddb869c52023-11-23T10:37:18ZengMDPI AGCurrent Oncology1198-00521718-77292022-05-012953531353910.3390/curroncol29050285Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with <i>EGFR</i> Gene Mutation–Case Report and a Literature ReviewAnna Rekowska0Piotr Rola1Magdalena Wójcik-Superczyńska2Izabela Chmielewska3Paweł Krawczyk4Janusz Milanowski5Student Scientific Association, Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, PolandStudent Scientific Association, Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-059 Lublin, PolandNon-small cell lung cancer (NSCLC) is the most common type of lung cancer and the leading cause of cancer-related mortality worldwide. It is responsible for 80–85% of lung cancer cases. NSCLC can be divided into several groups, led by adenocarcinoma (ADC)–40–50% and squamous cell carcinoma (SCC)–20–30%. The development of new molecular therapies targeting particular abnormalities such as mutations in the <i>EGFR</i> (<i>Epidermal Growth Factor Receptor</i>) gene or <i>ROS1</i> or <i>ALK</i> genes rearrangements resolved in novel strategies in advanced NSCLC management. <i>EGFR</i> mutation occurs mostly in patients with ADC and those patients are mostly females with no or light smoking history. The hereby presented patient fitted the ADC characteristics, while they were diagnosed with SCC. The unusual diagnosis implied further genetic testing, which established the occurrence of L858R substitution in exon 21 in the <i>EGFR</i> gene. A 63-year-old female was admitted to the unit due to a dry cough, pain in the right chest area and dyspnoea. When diagnosed, the patient had a peripheral mass in the right lung superior lobe (55 × 40 mm), satellite nodules in the apex of the same lung and packets of disintegrating lymph nodes. Positron Emission Tomography (PET-CT) confirmed a diffuse neoplastic process qualified as stage IV on the TNM scale. Due to <i>EGFR</i> gene mutation, the woman was administered osimertinib, however, the treatment did not succeed, and other therapeutic solutions were undertaken. The patient died 10 months after diagnosis. Patients with advanced ADC harboring <i>EGFR</i> mutation can receive osimertinib, a third-generation tyrosine kinase inhibitor (TKI), however, the use of TKIs in SCC remains controversial. In some published cases, osimertinib treatment led to success, in others, the therapy did not result in the expected final effect. Small sample groups and diverse molecular backgrounds indicate the need for further research in this field. Thus, the treatment decision-making process in those patients overall remains extremely demanding and ambiguous.https://www.mdpi.com/1718-7729/29/5/285osimertinibsquamous cell carcinomanon-small cell lung cancerEGFRTKIs |
| spellingShingle | Anna Rekowska Piotr Rola Magdalena Wójcik-Superczyńska Izabela Chmielewska Paweł Krawczyk Janusz Milanowski Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with <i>EGFR</i> Gene Mutation–Case Report and a Literature Review Current Oncology osimertinib squamous cell carcinoma non-small cell lung cancer EGFR TKIs |
| title | Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with <i>EGFR</i> Gene Mutation–Case Report and a Literature Review |
| title_full | Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with <i>EGFR</i> Gene Mutation–Case Report and a Literature Review |
| title_fullStr | Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with <i>EGFR</i> Gene Mutation–Case Report and a Literature Review |
| title_full_unstemmed | Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with <i>EGFR</i> Gene Mutation–Case Report and a Literature Review |
| title_short | Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with <i>EGFR</i> Gene Mutation–Case Report and a Literature Review |
| title_sort | efficacy of osimertinib in lung squamous cell carcinoma patients with i egfr i gene mutation case report and a literature review |
| topic | osimertinib squamous cell carcinoma non-small cell lung cancer EGFR TKIs |
| url | https://www.mdpi.com/1718-7729/29/5/285 |
| work_keys_str_mv | AT annarekowska efficacyofosimertinibinlungsquamouscellcarcinomapatientswithiegfrigenemutationcasereportandaliteraturereview AT piotrrola efficacyofosimertinibinlungsquamouscellcarcinomapatientswithiegfrigenemutationcasereportandaliteraturereview AT magdalenawojciksuperczynska efficacyofosimertinibinlungsquamouscellcarcinomapatientswithiegfrigenemutationcasereportandaliteraturereview AT izabelachmielewska efficacyofosimertinibinlungsquamouscellcarcinomapatientswithiegfrigenemutationcasereportandaliteraturereview AT pawełkrawczyk efficacyofosimertinibinlungsquamouscellcarcinomapatientswithiegfrigenemutationcasereportandaliteraturereview AT januszmilanowski efficacyofosimertinibinlungsquamouscellcarcinomapatientswithiegfrigenemutationcasereportandaliteraturereview |